Download presentation

Presentation is loading. Please wait.

Published byKierra Stackhouse Modified over 2 years ago

1
**Introduction to Biostatistics for Clinical and Translational Researchers**

KUMC Departments of Biostatistics & Internal Medicine University of Kansas Cancer Center FRONTIERS: The Heartland Institute of Clinical and Translational Research

2
**Course Information Jo A. Wick, PhD**

Office Location: Robinson Lectures are recorded and posted at under ‘Events & Lectures’

3
Objectives Understand the role of statistics in the scientific process and how it is a core component of evidence-based medicine Understand features, strengths and limitations of descriptive, observational and experimental studies Distinguish between association and causation Understand roles of chance, bias and confounding in the evaluation of research

4
**Course Calendar July 5: Introduction to Statistics: Core Concepts**

July 12: Quality of Evidence: Considerations for Design of Experiments and Evaluation of Literature July 19: Hypothesis Testing & Application of Concepts to Common Clinical Research Questions July 26: (Cont.) Hypothesis Testing & Application of Concepts to Common Clinical Research Questions

6
**Why is there conflicting evidence?**

Answer: There is no perfect research study. Every study has limitations. Every study has context. Medicine (and research!) is an art as well as a science. Unfortunately, the literature is full of poorly designed, poorly executed and improperly interpreted studies—it is up to you, the consumer, to critically evaluate its merit.

7
**Critical Evaluation Validity and Relevance**

Is the article from a peer-reviewed journal? How does the location of the study reflect the larger context of the population? Does the sample reflect the targeted population? Is the study sponsored by an organization that may influence the study design or results? Is the intervention feasible? available?

8
**Critical Evaluation Intent**

Therapy: testing the efficacy of drug treatments, surgical procedures, alternative methods of delivery, etc. (RCT) Diagnosis: demonstrating whether a new diagnostic test is valid (Cross-sectional survey) Screening: demonstrating the value of tests which can be applied to large populations and which pick up disease at a presymptomatic stage (Cross-sectional survey) Prognosis: determining what is likely to happen to someone whose disease is picked up at an early stage (Longitudinal cohort) Therapy--

9
Critical Evaluation Causation: determining whether a harmful agent is related to development of illness (Cohort or case-control)

10
**Critical Evaluation Validity based on intent**

What is the study design? Is it appropriate and optimal for the intent? Are all participants who entered the trial accounted for in the conclusion? What protections against bias were put into place? Blinding? Controls? Randomization? If there were treatment groups, were the groups similar at the start of the trial? Were the groups treated equally (aside from the actual intervention)?

11
Critical Evaluation If statistically significant, are the results clinically meaningful? If negative, was the study powered prior to execution? Were there other factors not accounted for that could have affected the outcome? Miser, WF Primary Care 2006.

12
Experimental Design Statistical analysis, no matter how intricate, cannot rescue a poorly designed study. No matter how efficient, statistical analysis cannot be done overnight. A researcher should plan and state what they are going to do, do it, and then report those results. Be transparent!

13
Types of Samples Random sample: each person has equal chance of being selected. Convenience sample: persons are selected because they are convenient or readily available. Systematic sample: persons selected based on a pattern. Stratified sample: persons selected from within subgroup.

14
Random Sampling For studies, it is optimal (but not always possible) for the sample providing the data to be representative of the population under study. Simple random sampling provides a representative sample (theoretically) and protections against selection bias. A sampling scheme in which every possible sub-sample of size n from a population is equally likely to be selected Assuming the sample is representative, the summary statistics (e.g., mean) should be ‘good’ estimates of the true quantities in the population. The larger n is, the better estimates will be.

15
Random Samples The Fundamental Rule of Using Data for Inference requires the use of random sampling or random assignment. Random sampling or random assignment ensures control over “nuisance” variables. We can randomly select individuals to ensure that the population is well-represented. Equal sampling of males and females Equal sampling from a range of ages Equal sampling from a range of BMI, weight, etc.

16
Random Samples Randomly assigning subjects to treatment levels to ensure that the levels differ only by the treatment administered. weights ages risk factors

17
Nuisance Variation Nuisance variation is any undesired sources of variation that affect the outcome. Can systematically distort results in a particular direction—referred to as bias. Can increase the variability of the outcome being measured—results in a less powerful test because of too much ‘noise’ in the data.

18
Example: Albino Rats It is hypothesized that exposing albino rats to microwave radiation will decrease their food consumption. Intervention: exposure to radiation Levels exposure or non-exposure Levels 0, 20000, 40000, uW Measurable outcome: amount of food consumed Possible nuisance variables: sex, weight, temperature, previous feeding experiences Weight is positively correlated with food consumption, so it could systematically distort the results. uW = microwatts

19
**Experimental Design Types of data collected in a clinical trial:**

Treatment – the patient’s assigned treatment and actual treatment received Response – measures of the patient’s response to treatment including side-effects Prognostic factors (covariates) – details of the patient’s initial condition and previous history upon entry into the trial

20
**Experimental Design Three basic types of outcome data:**

Qualitative – nominal or ordinal, success/failure, CR, PR, Stable disease, Progression of disease Quantitative – interval or ratio, raw score, difference, ratio, % Time to event – survival or disease-free time, etc.

21
Experimental Design Formulate statistical hypotheses that are germane to the scientific hypothesis. Determine: experimental conditions to be used (independent variable(s)) measurements to be recorded extraneous conditions to be controlled (nuisance variables)

22
Experimental Design Specify the number of subjects required and the population from which they will be sampled. Power, Type I & II errors Specify the procedure for assigning subjects to the experimental conditions. Determine the statistical analysis that will be performed.

23
**Experimental Design Considerations:**

Does the design permit the calculation of a valid estimate of treatment effect? Does the data-collection procedure produce reliable results? Does the design possess sufficient power to permit and adequate test of the hypotheses?

24
**Experimental Design Considerations:**

Does the design provide maximum efficiency within the constraints imposed by the experimental situation? Does the experimental procedure conform to accepted practices and procedures used in the research area? Facilitates comparison of findings with the results of other investigations Efficiency: When comparing competing designs, the design that can achieve the same precision with fewer resources is more efficient. This comes into play when we are powering the study—for a given precision, the more efficient design will require fewer subjects to be enrolled to achieve minimally acceptable power.

25
**Types of Studies Purpose of research**

To explore To describe or classify To establish relationships To establish causality Strategies for accomplishing these purposes: Naturalistic observation Case study Survey Quasi-experiment Experiment Ambiguity Control

26
**Complexity and Confidence**

1/9/2013 Generating Evidence Studies Descriptive Studies Populations Individuals Case Reports Case Series Cross Sectional Analytic Studies Observational Case Control Cohort Experimental RCT In fact, the quality of your evidence is not only dependent upon the size of your study but also on the study design you choose and implement. For instance, the literature may consist only of a few case reports and case series. These are very simple, observational, descriptive studies on individual patients and provided very little more than anecdotal data. They were, in essence, step 0. Any of the study designs to the right of these would provide stronger evidence, with the randomized controlled trial providing the strongest scientific evidence from the design perspective. Why do they increase in confidence? One reason is the size—case reports and case series are small, and in general RCTs are larger. Another reason is directly listed—they are more complex. And the reason they are more complex is because we are being deliberate about eliminating sources of bias and noise in order to get the most reliable estimates possible. In the next several slides we will discuss a few of the more common types of study designs. Complexity and Confidence

27
**Observation versus Experiment**

A designed experiment involves the investigator assigning (preferably randomly) some or all conditions to subjects. An observational study includes conditions that are observed, not assigned.

28
Example: Heart Study Question: How does serum total cholesterol vary by age, gender, education, and use of blood pressure medication? Does smoking affect any of the associations? Recruit n = 3000 subjects over two years Take blood samples and have subjects answer a CVD risk factor survey Outcome: Serum total cholesterol Factors: BP meds (observed, not assigned) Confounders?

29
Example: Diabetes Question: Will a new treatment help overweight people with diabetes lose weight? N = 40 obese adults with Type II (non-insulin dependent) diabetes (20 female/20 male) Randomized, double-blind, placebo-controlled study of treatment versus placebo Outcome: Weight loss Factor: Treatment versus placebo

30
**Cross-Sectional Studies**

Designed to assess the association between an independent variable (exposure?) and a dependent variable (disease?) Selection of study subjects is based on both their exposure and outcome status, thus there is no direction of inquiry

31
**Cross-Sectional Studies**

Defined Population Gather data on Exposure & Disease Exposed Diseased No Disease Not Exposed In a design like this, we can answer questions like—is disease independent of exposure, or does exposure increase/decrease the prevalence of disease? Often, a chi-square test or a fisher’s exact test would be used to answer these questions, since what you have is a correlation of two yes/no outcomes.

32
**Cross-Sectional Studies**

Cannot determine causal relationships between exposure and outcome Cannot determine temporal relationship between exposure and outcome “Exposure is associated with Disease” Some of the limitations include the inability to conclude causality and the lack of directional relationship. “Exposure causes Disease” “Disease follows Exposure”

33
**Analysis of Cross-Sectional Data**

Disease + - Exposure a b c d Prevalence of disease compared in exposed versus non-exposed groups: Prevalence of exposure compared in diseased versus non-diseased groups:

34
Case-Control Studies Designed to assess the association between disease and past exposures Selection of study subjects is based on their disease status Direction of inquiry is backward

35
**Case-Control Studies Exposed Unexposed Diseased Defined Population**

Gather data on Disease Diseased Unexposed Exposed No Disease Direction of Inquiry Cases and controls need to be from same source population Time

36
**Analysis of Case-Control Data**

Disease + - Total Exposure a b a+b c d c+d a+c b+d Odds ratio: odds of case exposure . odds of control exposure

37
Cohort Studies Designed to assess the association between exposures and disease occurrence Selection of study subjects is based on their exposure status Direction of inquiry is forward

38
**Gather data on Exposure**

Cohort Studies Defined Population Gather data on Exposure Exposed Disease No Disease Not Exposed Direction of Inquiry Concurrent or nonconcurrent cohorts; concurrent is referred to as prospective or longitudinal; nonconcurrent is retrospective or historical; Time

39
**Cohort Studies Attrition or loss to follow-up Time and money!**

Inefficient for very rare outcomes Bias Outcome ascertainment Information bias Non-response bias

40
**Analysis of Cohort Data**

Disease + - Total Exposure a b a+b c d c+d a+c b+d Relative Risk: risk of disease in exposed . risk of disease in unexposed

41
**Randomized Controlled Trials**

Designed to test the association between exposures and disease Selection of study subjects is based on their assigned exposure status Direction of inquiry is forward

42
**Randomized Controlled Trials**

Defined Population Randomize to Exposure Exposed (Treated) Disease No Disease Not Exposed (Control) Direction of Inquiry Concurrent or nonconcurrent cohorts; concurrent is referred to as prospective or longitudinal; nonconcurrent is retrospective or historical; Time

43
Why do we randomize? Suppose we wish to compare surgery for CAD to a drug used to treat CAD. We know that such major heart surgery is invasive and complex—some people die during surgery. We may assign the patients with less severe CAD (on purpose or not) to the surgery group. If we see a difference in patient survival, is it due to surgery versus drugs or to less severe disease versus more severe disease? Such a study would be inconclusive and a waste of time, money and patients.

44
**How could we fix it? Randomize!**

Randomization is critical because there is no way for a researcher to be aware of all possible confounders. Observational studies have little to no formal control for any confounders—thus we cannot conclude cause and effect based on their results. Randomization forms the basis of inference.

45
**Other Protections Against Bias**

Blinding Single (patient only), double (patient and evaluator), and triple (patient, evaluator, statistician) blinding is possible Eliminates biases that can arise from knowledge of treatment Control Null (no treatment), placebo (no active treatment), active (current standard of care) controls are used Eliminates biases that can arise from the natural progression of disease (null control) or simply from the act of being treated (placebo)

46
**Analysis of RCT Data What kind of outcome do you have?**

Continuous? Categorical? How many samples (groups) do you have? Are they related or independent?

47
Types of Tests Parametric methods: make assumptions about the distribution of the data (e.g., normally distributed) and are suited for sample sizes large enough to assess whether the distributional assumption is met Nonparametric methods: make no assumptions about the distribution of the data and are suitable for small sample sizes or large samples where parametric assumptions are violated Use ranks of the data values rather than actual data values themselves Loss of power when parametric test is appropriate

48
Analysis of RCT Data Two independent percentages? Fisher’s Exact test, chi-square test, logistic regression Two independent means? Mann-Whitney, Two-sample t-test, analysis of variance, linear regression Two independent time-to-event outcomes? Log-rank test, Wilcoxon test, Cox regression Any adjustments for other prognostic factors can be accomplished with the appropriate regression models (e.g., logistic for yes/no outcomes, linear for continuous, Cox for time-to)

49
**Threats to Valid Inference**

Statistical Conclusion Validity Low statistical power - failing to reject a false hypothesis because of inadequate sample size, irrelevant sources of variation that are not controlled, or the use of inefficient test statistics. Violated assumptions - test statistics have been derived conditioned on the truth of certain assumptions. If their tenability is questionable, incorrect inferences may result. Many methods are based on approximations to a normal distribution or another probability distribution that becomes more accurate as sample size increases—using these methods for small sample sizes may produce unreliable results.

50
**Threats to Valid Inference**

Statistical Conclusion Validity Reliability of measures and treatment implementation. Random variation in the experimental setting and/or subjects. Inflation of variability may result in not rejecting a false hypothesis (loss of power).

51
**Threats to Valid Inference**

Internal Validity Uncontrolled events - events other than the administration of treatment that occur between the time the treatment is assigned and the time the outcome is measured. The passing of time - processes not related to treatment that occur simply as a function of the passage of time that may affect the outcome.

52
**Threats to Valid Inference**

Internal Validity Instrumentation - changes in the calibration of a measuring instrument, the use of more than one instrument, shifts in subjective criteria used by observers, etc. The “John Henry” effect - compensatory rivalry by subjects receiving less desirable treatments. The “placebo” effect - a subject behaves in a manner consistent with his or her expectations.

53
**Threats to Valid Inference**

External Validity—Generalizability Reactive arrangements - subjects who are aware that they are being observed may behave differently that subjects who are not aware. Interaction of testing and treatment - pretests may sensitize subjects to a topic and enhance the effectiveness of a treatment.

54
**Threats to Valid Inference**

External Validity—Generalizability Self-selection - the results may only generalize to volunteer populations. Interaction of setting and treatment - results obtained in a clinical setting may not generalize to the outside world.

55
**Clinical Trials—Purpose**

Prevention trials look for more effective/safer ways to prevent a disease in individuals who have never had it, or to prevent a disease from recurring in individuals who have. Screening trials attempt to identify the best methods for detecting diseases or health conditions. Diagnostic trials are conducted to distinguish better tests or procedures for diagnosing a particular disease or condition.

56
**Clinical Trials—Purpose**

Treatment trials assess experimental treatments, new combinations of drugs, or new approaches to surgery or radiation therapy for efficacy and safety. Quality of life (supportive care) trials explore means to improve comfort and quality of life for individuals with chronic illness. Classification according to the U.S. National Institutes of Health

57
**Clinical Trials—Phases**

Pre-clinical studies involve in vivo and in vitro testing of promising compounds to obtain preliminary efficacy, toxicity, and pharmacokinetic information to assist in making decisions about future studies in humans.

58
**Clinical Trials—Phases**

Phase 0 studies are exploratory, first-in-human trials, that are designed to establish very early on whether the drug behaves in human subjects as was anticipated from preclinical studies. Typically utilizes N = 10 to 15 subjects to assess pharmacokinetics and pharmacodynamics. Allows the go/no-go decision usually made from animal studies to be based on preliminary human data.

59
**Clinical Trials—Phases**

Phase I studies assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of a drug in healthy volunteers (industry standard) or patients (academic/research standard). Involves dose-escalation studies which attempt to identify an appropriate therapeutic dose. Utilizes small samples, typically N = 20 to 80 subjects.

60
**Clinical Trials—Phases**

Phase II studies assess the efficacy of the drug and continue the safety assessments from phase I. Larger groups are usually used, N = 20 to 300. Their purpose is to confirm efficacy (i.e., estimation of effect), not necessarily to compare experimental drug to placebo or active comparator.

61
**Clinical Trials—Phases**

Phase III studies are the definitive assessment of a drug’s effectiveness and safety in comparison with the current gold standard treatment. Much larger sample sizes are utilized, N = 300 to 3,000, and multiple sites can be used to recruit patients. Because they are quite an investment, they are usually randomized, controlled studies.

62
**Clinical Trials—Phases**

Phase IV studies are also known as post-marketing surveillance trials and involve the ongoing or long-term assessment of safety in drugs that have been approved for human use. Detect any rare or long-term adverse effects in a much broader patient population

63
**The Size of a Clinical Trial**

Lasagna’s Law Once a clinical trial has started, the number of suitable patients dwindles to a tenth of what was calculated before the trial began.

64
**The Size of a Clinical Trial**

“How many patients do we need?” Statistical methods can be used to determine the required number of patients to meet the trial’s principal scientific objectives. Other considerations that must be accounted for include availability of patients and resources and the ethical need to prevent any patient from receiving inferior treatment. We want the minimum number of patients required to achieve our principal scientific objective.

65
**The Size of a Clinical Trial**

Estimation trials involve the use of point and interval estimates to describe an outcome of interest. Hypothesis testing is typically used to detect a difference between competing treatments.

66
**The Size of a Clinical Trial**

Type I error rate (α): the risk of concluding a significant difference exists between treatments when the treatments are actually equally effective. Type II error rate (β): the risk of concluding no significant difference exists between treatments when the treatments are actually different.

67
**The Size of a Clinical Trial**

Power (1 – β): the probability of correctly detecting a difference between treatments—more commonly referred to as the power of the test. Truth Conclusion H1 H0 1 – β α β 1 – α

68
**The Size of a Clinical Trial**

Setting three determines the fourth: For the chosen level of significance (α), a clinically meaningful difference (δ) can be detected with a minimally acceptable power (1 – β) with n subjects. Depending on the nature of the outcome, the same applies: For the chosen level of significance (α), an outcome can be estimated within a specified margin of error (ME) with n subjects.

69
**Example: Detecting a Difference**

The Anturane Reinfarction Trial Research Group (1978) describe the design of a randomized double-blind trial comparing anturan and placebo in patients after a myocardial infarction. What is the main purpose of the trial? What is the principal measure of patient outcome? How will the data be analyzed to detect a treatment difference? What type of results does one anticipate with standard treatment? How small a treatment difference is it important to detect and with what degree of uncertainty?

70
**Example: Detecting a Difference**

Primary objective: To see if anturan is of value in preventing mortality after a myocardial infarction. Primary outcome: Treatment failure is indicated by death within one year of first treatment (0/1). Data analysis: Comparison of percentages of patients dying within first year on anturan (π1) versus placebo (π2) using a χ2 test at the α = 0.05 level of significance.

71
**Example: Detecting a Difference**

Expected results under placebo: One would expect about 10% of patients to die within a year (i.e., π2 = .1). Difference to detect (δ): It is clinically interesting to be able to determine if anturan can halve the mortality—i.e., 5% of patients die within a year—and we would like to be 90% sure that we detect this difference as statistically significant.

72
**Example: Detecting a Difference**

We have: H0: π1 = π2 versus H1: π1 π2 (two-sided test) α = 0.05 1 – β = 0.90 δ = π2 – π1 = 0.05 The estimate of power for this test is a function of sample size: n = 583 patients per group is required

73
**Example: Detecting a Difference**

1 - β β α/2 1 - α α/2 -zα/2 zα/2 Reject H0 Conclude difference Fail to reject H0 Conclude no difference Reject H0 Conclude difference

74
Power and Sample Size n is roughly inversely proportional to δ2; for fixed α and β, halving the difference in rates requiring detection results in a fourfold increase in sample size. n depends on the choice of β such that an increase in power from 0.5 to 0.95 requires around 3 times the number of patients. Reducing α from 0.05 to 0.01 results in an increase in sample size of around 40% when β is around 10%. Using a one-sided test reduces the required sample size.

75
**Example: Detecting a Difference**

Primary objective: To see if treatment A increases outcome W. Primary outcome: The primary outcome, W, is continuous. Data analysis: Comparison of mean response of patients on treatment A (μ1) versus placebo (μ2) using a two-sided t-test at the α = 0.05 level of significance.

76
**Example: Detecting a Difference**

Expected results under placebo: One would expect a mean response of 10 (i.e., μ2 = 10). Difference to detect (δ): It is clinically interesting to be able to determine if treatment A can increase response by 10%—i.e., we would like to see a mean response of 11 (10 + 1) in patients getting treatment A and we would like to be 80% sure that we detect this difference as statistically significant.

77
**Example: Detecting a Difference**

We have: H0: μ1 = μ2 versus H1: μ1 μ2 (two-sided test) α = 0.05 1 – β = 0.80 δ = 1 For continuous outcomes we need to determine what difference would be clinically meaningful, but specified in the form of an effect size which takes into account the variability of the data.

78
**Example: Detecting a Difference**

Effect size is the difference in the means divided by the standard deviation, usually of the control or comparison group, or the pooled standard deviation of the two groups where

79
**Example: Detecting a Difference**

1 - β β α/2 1 - α α/2 -zα/2 zα/2 Reject H0 Conclude difference Fail to reject H0 Conclude no difference Reject H0 Conclude difference

80
**Example: Detecting a Difference**

Power Calculations an interesting interactive web-based tool to show the relationship between power and the sample size, variability, and difference to detect. A decrease in the variability of the data results in an increase in power for a given sample size. An increase in the effect size results in a decrease in the required sample size to achieve a given power. Increasing α results in an increase in the required sample size to achieve a given power.

81
Prognostic Factors It is reasonable and sometimes essential to collect information of personal characteristics and past history at baseline when enrolling patient’s onto a clinical trial. These variables allow us to determine how generalizable the results are.

82
Prognostic Factors Prognostic factors known to be related to the desired outcome of the clinical trial must be collected and in some cases randomization should be stratified upon these variables. Many baseline characteristics may not be known to be related to outcome, but may be associated with outcome for a given trial.

83
**Comparable Treatment Groups**

All baseline prognostic and descriptive factors of interest should be summarized between the treatment groups to insure that they are comparable between treatments. It is generally recommended that these be descriptive comparisons only, not inferential Note: Just because a factor is balanced does not mean it will not affect outcome and vice versa.

84
Subgroup Analysis Does response differ for differing types of patients? This is a natural question to ask. To answer this question one should test to see if the factor that determines type of patient interacts with treatment. Separate significance tests for different subgroups do not provide direct evidence of whether a prognostic factor affects the treatment difference: a test for interaction is much more valid. Tests for interactions may also be designed a priori.

85
Multiplicity of Data Multiple Treatments – the number of possible treatment comparisons increases rapidly with the number of treatments. (Newman-Keuls, Tukey’s HSD or other adjustment should be designed) Multiple end-points – there may be multiple ways to evaluate how a patient responds. (Bonferroni adjustment, Multivariate test, combined score, or reduce number of primary end-points)

86
Multiplicity of Data Repeated Measurements – patient’s progress may be recorded at several fixed time points after the start of treatment. One should aim for a single summary measure for each patient outcome so that only one significance test is necessary. Subgroup Analyses – patients may be grouped into subgroups and each subgroup may be analyzed separately. Interim Analyses – repeated interim analyses may be performed after accumulating data while the trial is in progress.

87
Summary Statistics plays a key role in pre-clinical and clinical research Statistics helps us determine how ‘confident’ we should be in the results of a study Confidence in a study is based on (1) the size of the study, (2) its safeguards against biases (complexity), (3) how it was actually undertaken Statistical support is available and should be sought out as early as possible in the process of designing a study

88
**Next Time . . . Basic Descriptive and Inferential Methods**

Hypothesis Testing P-values Confidence Intervals Interpretation Examples

Similar presentations

© 2017 SlidePlayer.com Inc.

All rights reserved.

Ads by Google